Fischer Medical Share Price in Focus; Revenue Slips QoQ in Q1 FY26 Results

Fischer Medical Ventures Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.

Revenue from Operations

For the quarter ended June 30, 2025, the company reported a standalone revenue from operations of ₹454.23 lakh, compared to ₹521.97 lakh in the previous quarter ended March 31, 2025. On a consolidated basis, revenue from operations stood at ₹2,344.47 lakh, reflecting a decline from ₹4,917.42 lakh reported in the previous quarter.

Total Income

The standalone total income for Q1 FY26 was ₹534.63 lakh, down from ₹586.90 lakh in Q4 FY25. On the consolidated front, total income came in at ₹3,091.11 lakh, also lower compared to ₹4,932.29 lakh reported in the preceding quarter. This indicates a slowdown in operational and other income streams during the quarter.

Profit After Tax (PAT)

Fischer Medical Ventures reported a standalone net loss of ₹60.94 lakh for Q1 FY26, compared to a loss of ₹89.05 lakh in the previous quarter, showing slight improvement. On a consolidated level, the company posted a profit after tax of ₹500.82 lakh for the quarter, against ₹131.22 lakh in Q4 FY25, reflecting significant growth in consolidated profitability.

Fischer Medical Share Price Performance

On August 18, 2025, Fischer Medical share price (NSE: FISCHER) opened at ₹1,013.35, touching the day’s high at ₹1,025.00, as of 11:21 AM on the NSE.

Also Read: Fischer Medical Ventures Acquires Key Property in Malaysia for Healthcare Hub! 

Conclusion

While standalone results continue to show a net loss, Fischer Medical Ventures Ltd delivered consolidated profit growth in Q1 FY26. The improvement in consolidated PAT demonstrates resilience in the company’s broader operations, though the decline in revenue and total income signals a need for sustained focus on revenue generation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.